Cingulate Inc (CING)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$4.98+6.87%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cingulate Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	2.36M
EPS	—	-0.43
Annual ending 2026-12-31
Revenue	—	2.9M
EPS	—	-2.133
Annual ending 2027-12-31
Revenue	—	12.17M
EPS	—	-1.753

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Utilize $12M private placement proceeds effectively	A supporting condition in Cingulate Inc's published investment case. The stated target is Sustain operations using $12 million raised in private placements.	Improving	Capital runs out before end of FY26 without further funding	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Resubmit CTx-1301 NDA to FDA	Cingulate plans to resubmit the CTx-1301 NDA promptly after FDA feedback.	Improving	NDA resubmission delayed beyond next 4 quarters	Qualitative: PK study published (Aug 2026) post-CRL (Jun 2026) FDA CRL received in June 2026; subsequent PK study publication in August 2026 supports NDA resubmission efforts. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management emphasizes completing CMC work and resubmitting the NDA promptly following the FDA's June 1, 2026 Complete Response Letter. The company is actively working with its manufacturing partner and FDA, showing delivering progress on regulatory engagement and preparation for resubmission. Delivery assessment Oct 24, 2026
Manage operating losses near -$7.9M Q1 2026 level	Operating losses are managed near -$7.9 million in Q1 2026.	Intact	Operating loss worsens beyond -$7.9 million per quarter	Operating income: $-5.415M FY2026-Q2; GAAP. Published target: Operating loss no worse than -$7.9 million per quarter. Target period is not explicitly aligned with this observation. Source published Aug 13, 2026-5,414,975 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 07508b7c-6cd3-4ee9-9b11-0f9b11b5086c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Net loss increased from $5.0 million in 2025-Q2 to $5.9 million in 2026-Q2, reflecting higher SG&A expenses for commercial readiness despite reduced R&D costs. Management continues to manage operating losses amid advancing development and commercialization efforts, showing limited progress in reducing net losses. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

$0.02B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$17,007,667	4 / 5
2026-07-25	Unavailable	$17,007,667	4 / 5
2026-07-26	Unavailable	$17,007,667	4 / 5
2026-07-27	Unavailable	$17,007,667	4 / 5
2026-07-28	Unavailable	$17,007,667	4 / 5
2026-07-29	Unavailable	$17,007,667	4 / 5
2026-07-30	Unavailable	$17,007,667	4 / 5
2026-07-31	Unavailable	$17,007,667	4 / 5
2026-08-01	Unavailable	$17,007,667	4 / 5
2026-08-02	Unavailable	$17,007,667	4 / 5
2026-08-03	Unavailable	$17,007,667	4 / 5
2026-08-04	Unavailable	$17,007,667	4 / 5
2026-08-05	Unavailable	$17,007,667	4 / 5
2026-08-06	Unavailable	$17,007,667	4 / 5
2026-08-07	Unavailable	$17,007,667	4 / 5
2026-08-08	Unavailable	$20,035,800	4 / 5
2026-08-09	Unavailable	$20,035,800	4 / 5
2026-08-10	Unavailable	$20,035,800	4 / 5
2026-08-11	Unavailable	$17,007,667	4 / 5
2026-08-12	Unavailable	$20,035,800	4 / 5
2026-08-13	Unavailable	$17,007,667	4 / 5
2026-08-14	Unavailable	$17,007,667	4 / 5
2026-08-15	Unavailable	$17,007,667	4 / 5
2026-08-16	Unavailable	Unavailable	4 / 4
2026-08-17	Unavailable	Unavailable	4 / 4
2026-08-18	Unavailable	Unavailable	4 / 4
2026-08-19	Unavailable	$17,007,667	4 / 5
2026-08-20	Unavailable	$17,007,667	4 / 5
2026-08-21	Unavailable	$19,924,167	4 / 5
2026-08-22	Unavailable	$19,924,167	4 / 5
2026-08-23	Unavailable	$19,924,167	4 / 5
2026-08-24	Unavailable	$19,924,167	4 / 5
2026-08-25	Unavailable	$19,924,167	4 / 5
2026-08-26	Unavailable	$19,924,167	4 / 5
2026-08-27	Unavailable	$19,924,167	4 / 5
2026-08-28	Unavailable	$19,924,167	4 / 5
2026-08-29	Unavailable	$19,924,167	4 / 5
2026-08-30	Unavailable	$19,924,167	4 / 5
2026-08-31	Unavailable	$19,924,167	4 / 5
2026-09-01	Unavailable	$19,924,167	4 / 5
2026-09-02	Unavailable	$19,924,167	4 / 5
2026-09-03	Unavailable	$19,924,167	4 / 5
2026-09-04	Unavailable	$8,929,000	4 / 5
2026-09-05	Unavailable	$8,929,000	4 / 5
2026-09-06	Unavailable	$8,929,000	4 / 5
2026-09-07	Unavailable	$8,929,000	4 / 5
2026-09-08	Unavailable	$8,929,000	4 / 5
2026-09-09	Unavailable	$8,929,000	4 / 5
2026-09-10	Unavailable	$8,929,000	4 / 5
2026-09-11	Unavailable	$8,929,000	4 / 5
2026-09-12	Unavailable	$12,168,000	4 / 5
2026-09-13	Unavailable	$12,168,000	4 / 5
2026-09-14	Unavailable	$12,168,000	4 / 5
2026-09-15	Unavailable	$12,168,000	4 / 5
2026-09-16	Unavailable	$12,168,000	4 / 5
2026-09-17	Unavailable	$12,168,000	4 / 5
2026-09-18	Unavailable	$12,168,000	4 / 5
2026-09-19	Unavailable	$12,168,000	4 / 5
2026-09-20	Unavailable	$12,168,000	4 / 5
2026-09-21	Unavailable	$12,168,000	4 / 5
2026-09-22	Unavailable	$12,168,000	4 / 5
2026-09-23	Unavailable	$12,168,000	4 / 5
2026-09-24	Unavailable	$12,168,000	4 / 5
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	Unavailable	Unavailable	4 / 4
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	0	0
2026-06-01	4	0	0
2026-07-01	4	0	0
2026-08-01	4	0	0
2026-09-01	4	0	0
2026-10-01	4	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Utilize $12M private placement proceeds effectivelyDirect metric needs a verified mapping
Manage operating losses near -$7.9M Q1 2026 levelOperating income: $-5.415M

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-69.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cingulate Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making biotech with a regulatory and commercial execution thesis, not an established earnings compounder. The thesis is in a watch state, with low confidence and volatile management signals.

What's priced into Cingulate Inc

The evidence does not provide a valuation measure or a clear account of market expectations, so whether CING is cheap or expensive versus peers is unclear. The muted share-price reaction suggests recent developments have not led to a strong market response, but does not show what expectations are already priced in.

What the fundamentals likely do

Near term, earnings quality remains weak, and the risk of an earnings miss is elevated; recent financial performance is neutral and below its industry cohort. Management is working with its manufacturing partner and the FDA on resubmitting CTx-1301 after a Complete Response Letter, while commercial-readiness spending has increased. Cash rose to $28.4 million by 2026-Q2, extending the stated runway into mid-2027, though execution and funding remain important risks.

What Cingulate Inc hinges on

The multi-year thesis depends on completing the required CMC work and successfully resubmitting the CTx-1301 application, followed by readiness to launch. A weakening jobs report could increase recession concerns for cyclical names, while continued strength or weakness among healthcare bellwethers could support or weaken the sector backdrop. Evidence on the product’s regulatory progress and the company’s financial runway is limited.